Two New Zealand psychiatrists have won approval to prescribe pharmaceutical-grade MDMA to patients with severe post-traumatic stress disorder, making the country only the second in the world - after Australia in 2023 - to authorise the party drug for clinical use.
New Zealand's medicines regulator, Medsafe, granted the approvals to Wellington's Dr Gary Wynn and Auckland's Dr Tom Paterson, who spent more than a year passing the regulatory process.
